The FBN1 gene gives the body instructions for fibrillin-1, a protein that helps build strong, stretchy connective tissue in the heart, blood vessels, eyes, bones, and skin. When this gene does not work properly, supportive tissues can become too loose or fragile. Pathogenic variants in the FBN1 gene are a main cause of Marfan syndrome, which may involve being tall with long arms and fingers, changes in the eye lens, and widening of the aorta, the body’s main artery.
What is a gene?
A gene is a stretch of DNA that carries information your cells use to make molecules or regulate processes in the body. Some genes provide the instructions for proteins, the parts of cells that do the work. Others mainly help control when certain processes happen, where they happen, and how strongly they run. Taken together, genes influence how the body develops and functions, and they can shape how you respond to food, stress, or medications. For a more detailed look at this topic, you can visit the LearnHub.
Overview
FBN1Gene function
What if the gene works
The FBN1 gene makes fibrillin-1, a protein that helps build connective tissue. It supports stretchy fibers in the aorta, ligaments, skin, and eyes, helping these tissues stay strong and flexible.
Risk
What if the gene does not work
Variants in the FBN1 gene often cause Marfan syndrome, with aortic enlargement, lens dislocation, and long-limbed skeletal features. Milder to more severe variants can change when problems appear and how strongly the heart, eyes, and bones are affected.
Treatment
What does that mean for your treatment
In people with a pathogenic variant in the FBN1 gene, long term treatment often includes a beta blocker or an angiotensin receptor blocker such as losartan to help slow enlargement of the aorta. Management also shapes when preventive aortic surgery is considered, based on aortic size, growth, and family history.
Conditions associated with FBN1
Gene function
What if the gene works
Your connective tissues need both strength and flexibility for everyday movement and blood flow. The FBN1 gene provides instructions for fibrillin-1, a protein that helps build the fine support fibers around cells. Understanding how the FBN1 gene supports connective tissue helps explain how tissues keep their shape while still stretching and springing back.
Fibrillin-1 forms tiny fibers outside cells that give connective tissue shape and support. These fibers help tissues stay organized while they handle everyday pulling, bending, and pressure.
Fibrillin-1 helps create the scaffold for elastic fibers, which let tissues stretch and then return to their usual shape. This support matters in places like artery walls, lungs, and skin, where controlled flexibility is part of normal function.
Fibrillin-1 also helps manage growth signals around cells, including transforming growth factor beta (a signal that guides tissue growth and repair). This helps tissue building and upkeep stay more controlled over time.
What is a variant?
A genetic variant is a minor change in the DNA sequence of a gene. These changes are common and are part of normal human diversity, including differences in appearance, metabolism, or how the body responds to environmental influences. Many have no noticeable effect and simply represent natural genetic variation. In some situations, though, a variant changes how a gene functions more substantially and may contribute to or cause a genetic condition.
Genetic variants
What if the gene does not work
FBN1 gene variants often change the shape, stability, or release of fibrillin-1, so connective tissue fibers are built less reliably. Some variants mainly reduce how much protein cells make, while others create an altered protein that can disrupt the fibers it joins; this helps explain how FBN1 gene variants affect protein function. Milder variants may leave partial function, while more severe variants can be linked to earlier or more marked Marfan-related features.
How variants are linked to conditions
Pathogenic variants in the FBN1 gene are best known for causing Marfan syndrome, a connective tissue condition that can affect the heart, blood vessels, eyes, and skeleton. FBN1 gene variants are also linked to isolated ectopia lentis, MASS phenotype, and some inherited thoracic aortic aneurysm and dissection. More rarely, specific FBN1 variants cause conditions such as acromicric dysplasia, geleophysic dysplasia, and Weill-Marchesani syndrome.
A variant is not necessarily a diagnosis
Genetic variants are common across the general population and are a normal feature of human biology. Most do not directly affect health and simply reflect natural differences between people. For many genes, having a variant associated with a condition points to a possible link rather than a certain diagnosis, particularly when several genes and environmental influences play a role. In some situations, though, one well-characterized variant in a particular gene is enough to confirm the diagnosis.
Are there things that can increase or change my risk?
For FBN1, the main driver of risk is having a disease-causing gene change, often inherited in families, though it can also happen for the first time in one person. In people living with an FBN1-related condition, high blood pressure, smoking, pregnancy, and heavy straining or intense exercise can raise the risk of heart and blood vessel complications.
Inheritance of FBN1 variants
Most disease causing changes in the FBN1 gene are inherited in an autosomal dominant pattern, which means a child can inherit the variant from either parent and each pregnancy has a 50% chance of passing it on. This is the main answer to how FBN1 variants are inherited in families. Some people with an FBN1 related condition have a new, de novo variant, meaning it started in them and was not inherited from either parent. Once a person carries the variant, they can pass it to sons or daughters equally.
What does my FBN1 result mean for my family?
A disease-causing change in the FBN1 gene is usually passed in a dominant way, so close relatives such as a parent, brother, sister, or child may also carry the same change and may want to discuss testing. Each child of someone with an FBN1-related condition has a 1 in 2, or 50%, chance of inheriting it. Some cases happen for the first time in one person, so a parent may not have the same gene change.
Genetic information
Genetic testing
How you find out about variants
FBN1 genetic testing uses a blood or saliva sample to read the DNA code of the FBN1 gene and look for variants. Results may help explain findings linked to Marfan syndrome or related connective tissue conditions, and they are reported as pathogenic, benign, or uncertain depending on the evidence.
When should I consider getting a genetic test?
Consider FBN1 testing if you or a close relative has signs of Marfan syndrome, such as widening of the aorta, the body’s main blood vessel, an eye lens that has moved out of place, or a very tall build with long arms and fingers. It can also help when these findings run in the family or after an aortic tear at a young age.
A genetic result is only one part of your health story
Genetic results can be informative, but how much they reveal varies based on the condition and the kind of variant involved. Many factors, including lifestyle, environment, age, and medical history, influence how the body functions over time. In some conditions, especially those shaped by many genes, genetic information provides context rather than certainty and is best considered alongside other parts of care. In other situations, a genetic result may offer a clear answer. In areas like medication response, genetic results can also help put individual experiences into context.
Pharmacogenetics
How variants shape your response to medicine
Genetic variation can affect how your body responds to medicines. Some people process a drug more slowly or more quickly, while others are more or less sensitive to its effects. This helps explain why the same treatment can work well for one person but lead to more side effects or less benefit for another. These differences are common and are only one part of the picture, alongside age, overall health, and other medicines you take.
What is Pharmacogenetics?
Pharmacogenetics examines how differences in genes can affect the way people respond to medicines. It studies gene and drug patterns to help explain why the same treatment may work differently in different people. With many medications, genes can influence how the body breaks down a drug or how strong its effects are. This information can support treatment choices that are more informed and more tailored to the individual. More detail on this topic is available in the LearnHub.
Drugs influenced by the FBN1 gene
When should I seek medical advice?
There is not yet a broadly confirmed role for this gene in guiding medication choices, so general questions about medicines, side effects, or new symptoms are best discussed with your doctor.
History
Throughout history, people described tall stature, long limbs, and eye and heart findings that were later recognized as part of Marfan syndrome. First described in the medical literature in 1896 by Antoine Marfan, the condition was initially understood only through visible features seen in children and families. In the late 20th century, researchers linked many cases to the FBN1 gene, which marked a major step in showing how a single inherited gene change could shape connective tissue conditions. From these first observations, research expanded steadily. Finding the FBN1 gene helped clarify why related conditions can overlap and why the same diagnosis may look different from one person to another. This history still shapes how clinicians recognize and confirm Marfan syndrome today.